HCG

What Is HCG?

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy by the developing placenta's syncytiotrophoblast cells. It is a 237-amino acid heterodimer consisting of two non-covalently linked subunits: a 93-amino acid α-subunit (14.5 kDa) and a 145-amino acid β-subunit (22.2 kDa). The α-subunit is structurally homologous to luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and follicle-stimulating hormone (FSH), while the β-subunit is 80–85% homologous to LH — which is why HCG binds to and activates the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) with high affinity.

Originally discovered in the 1920s and first extracted for clinical use in the 1940s, HCG has been one of the most extensively studied reproductive hormones in medicine. Its primary natural role is to maintain the corpus luteum during early pregnancy, ensuring continued progesterone production until the placenta takes over steroidogenesis. However, its LH-mimicking properties have made it clinically valuable far beyond obstetrics — particularly in the fields of endocrinology, fertility medicine, and hormonal optimisation research.

In the research peptide context, HCG is valued for its ability to stimulate endogenous testosterone production in men, prevent testicular atrophy during androgen therapy, support fertility preservation, and potentially influence fat metabolism and body composition. Unlike synthetic peptide analogues in the Riptide Health catalogue, HCG is a naturally occurring hormone rather than a modified peptide — and its dosing is expressed in International Units (IU) rather than micrograms.

"HCG can activate various signaling cascades including Smad2, protein kinase C (PKC), and/or protein kinase A (PKA) in several cell types by binding to luteinizing hormone/chorionic gonadotropin receptor (LHCGR)." — Nwabuobi et al., International Journal of Molecular Sciences (2017)

---

How It Works — Mechanism of Action

1. LHCGR Activation and the cAMP/PKA Cascade HCG binds to the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), a G-protein coupled receptor expressed on Leydig cells in the testes (men) and theca/luteal cells in the ovaries (women). Receptor binding activates adenylate cyclase, converting ATP to cyclic AMP (cAMP), which in turn activates protein kinase A (PKA). This cascade stimulates steroidogenesis — the conversion of cholesterol to testosterone in men and progesterone/estradiol in women.

2. Testosterone Production in Men (Leydig Cell Stimulation) In males, HCG acts as an LH analogue, directly stimulating Leydig cells in the testes to produce testosterone. This is the primary mechanism underlying HCG's use in testosterone support research and as an adjunct to testosterone replacement therapy (TRT). By maintaining endogenous testosterone production, HCG helps prevent the HPTA (hypothalamic-pituitary-testicular axis) shutdown that occurs with exogenous testosterone administration.

3. Testicular Atrophy Prevention Exogenous testosterone suppresses LH production via negative feedback, leading to testicular shrinkage. HCG's LH-mimicking activity maintains testicular function and size by providing the trophic stimulus that endogenous LH would normally provide. This is well-documented in clinical literature on TRT adjunct protocols.

4. Spermatogenesis Support HCG supports spermatogenesis indirectly by maintaining intratesticular testosterone levels, which are essential for sperm production. HCG also interacts with FSH pathways to support the Sertoli cell environment necessary for spermatogenesis. This is the basis for HCG's use in male fertility preservation research.

5. Ovulation Induction and Corpus Luteum Support in Women In females, HCG mimics the mid-cycle LH surge that triggers ovulation. It also maintains the corpus luteum, ensuring continued progesterone production during the luteal phase. This is the basis for HCG's extensive clinical use in fertility medicine and ovulation induction protocols.

6. Potential Lipolysis and Metabolic Effects HCG may influence fat metabolism through several proposed mechanisms: direct action on LHCGR expressed in adipose tissue, modulation of hypothalamic signalling affecting appetite and fat mobilisation, and preservation of lean muscle mass during caloric restriction. While the "HCG diet" (very-low-calorie plus HCG injections) remains controversial and is not approved by regulatory authorities, the underlying lipolysis mechanisms continue to be investigated in research settings.

7. Immunomodulatory Activity HCG displays immunomodulatory properties, including alteration of dendritic cell activity, reduction of T-cell activation and cytokine production, promotion of T regulatory (Treg) cell recruitment, and increased proliferation of uterine natural killer (NK) cells. These effects, discovered through pregnancy immunology research, suggest potential applications beyond reproductive medicine.

---

Research-Backed Benefits

Testosterone Support & Endogenous Production

• Directly stimulates Leydig cell testosterone production via LHCGR activation
• Restores endogenous testosterone in men with secondary hypogonadism
• Maintains intratesticular testosterone levels during TRT — studies show HCG co-administration maintains intratesticular testosterone even when exogenous testosterone suppresses endogenous LH
• Provides an alternative to exogenous testosterone for men seeking to restore natural production

Fertility Preservation

• Prevents testicular atrophy in men undergoing TRT — maintains testicular size and function
• Supports spermatogenesis by maintaining intratesticular testosterone
• Preserves fertility in men on androgen therapy
• In women, supports ovulation induction and luteal phase progesterone production
• Clinical studies support HCG therapy to recover spermatogenesis after testosterone use

HPTA Support & Post-Cycle Recovery

• Mimics endogenous LH to maintain testicular function during periods of HPTA suppression
• Supports recovery of the hypothalamic-pituitary-testicular axis following androgen or prohormone cycles
• May accelerate restoration of natural testosterone production when exogenous hormones are discontinued

Body Composition & Fat Metabolism

• May enhance lipolysis and fat mobilisation through LHCGR activation in adipose tissue
• May reduce appetite through hypothalamic signalling modulation
• Preserves lean muscle mass during caloric restriction
• Potential applications in metabolic health and body composition research

Energy, Mood & Libido

• Improved energy levels and mental clarity reported in clinical use
• Enhanced motivation and mood — likely resulting from improved hormonal milieu
• Supports libido through both testosterone production and direct neuroendocrine effects
• Neurotransmitter modulation may contribute to mood-stabilising effects

---

Dosing & Administration

Available Route: Subcutaneous Injection

HCG is supplied as lyophilised powder and is administered via subcutaneous injection. Subcutaneous administration has been demonstrated to be as effective as intramuscular administration in terms of steroidogenesis, with the added benefit of easier self-administration and reduced injection site discomfort.

HCG dosing is expressed in International Units (IU) rather than micrograms, reflecting its identity as a bioactive hormone rather than a synthetic peptide.

Sub-Q Administration Protocols

TRT Adjunct / Testosterone Support

Post-Cycle Therapy (PCT) / HPTA Recovery

Note: PCT protocols are typically followed by a SERM (selective estrogen receptor modulator) phase for comprehensive HPTA recovery.

Fertility / Spermatogenesis Support

Injection Technique:

• Inject subcutaneously into the abdomen (preferred) or outer thigh — pinch the skin and insert at 45°
• Use a U-100 insulin syringe for accurate IU measurement
• Rotate injection sites to prevent localised irritation
• Subcutaneous administration is clinically validated as equally effective to intramuscular for steroidogenic purposes

Timing

• HCG can be administered at any time of day, though many protocols recommend morning dosing
• When used as a TRT adjunct, HCG is typically administered on days between testosterone injections
• For PCT, HCG is typically initiated 3–5 days after the last exogenous androgen dose

Cycle Rationale

• For TRT adjunct: continuous low-dose administration is standard — HCG maintains testicular function without the need for cycling
• For PCT: 2–3 week duration is standard, followed by SERM therapy — prolonged high-dose HCG can cause desensitisation of Leydig cells
• For fertility: extended protocols (3–6+ months) may be required for spermatogenesis recovery
• Doses above 5,000 IU in a single injection are not recommended due to risk of Leydig cell desensitisation

Storage

• Lyophilised (unreconstituted): Store at 2–8°C (refrigerated). Stable for up to 24 months when sealed and refrigerated. Can be stored at room temperature (15–25°C) for shorter periods if necessary.
• Reconstituted: Refrigerate at 2–8°C. Use within 30–60 days (varies by manufacturer — follow specific product guidelines). Do not freeze. Protect from light. Avoid repeated freeze-thaw cycles.

---

Side Effects & Safety

HCG has an extensive clinical safety record spanning decades of use in fertility medicine and endocrinology. When used at appropriate doses, it is generally well-tolerated.

Commonly reported (mild and transient):

• Mild injection site irritation, redness, or swelling — typical of sub-Q injection
• Headache
• Fatigue or irritability
• Water retention or bloating — due to increased estrogen from testosterone aromatisation
• Mood swings — typically dose-dependent

Less commonly reported:

• Gynecomastia (breast tissue growth in men) — caused by increased testosterone aromatising to estradiol; dose-dependent
• Acne or skin changes — related to increased androgen activity
• Elevated hematocrit — increased red blood cell production
• Breast tenderness
• Dizziness or restlessness

Rare but serious:

• Ovarian Hyperstimulation Syndrome (OHSS) — in women receiving high-dose HCG for ovulation induction; characterised by ovarian enlargement, fluid retention, and abdominal pain
• Leydig cell desensitisation — with prolonged high-dose use (doses >5,000 IU); can temporarily reduce testicular responsiveness to endogenous LH
• Hypersensitivity/allergic reactions — rare but possible

Important Safety Notes:

• HCG can elevate estrogen levels through increased aromatisation of testosterone to estradiol — monitor for signs of excess estrogen (gynecomastia, water retention, mood changes)
• Men with pre-existing prostate conditions should exercise caution — HCG-stimulated testosterone production may affect prostate tissue
• HCG is not recommended for individuals with hormone-sensitive cancers
• Prolonged high-dose HCG use can cause Leydig cell desensitisation — cycle appropriately and avoid excessive doses
• HCG may interfere with certain laboratory hormone tests — inform your healthcare provider of HCG use before hormone testing
• Discontinue use and consult a healthcare professional if any adverse reactions occur

---

Synergy Stacks

HCG + TRT (Testosterone Replacement Therapy) The most clinically established HCG stack. HCG prevents HPTA shutdown and testicular atrophy while exogenous testosterone provides the primary androgen replacement. Standard protocol: 250–500 IU HCG 2–3× weekly alongside TRT.

HCG + CJC-1295 / Ipamorelin Combining HCG's testosterone support with growth hormone secretagogue activity creates a comprehensive hormonal optimisation protocol — addressing both the androgen and GH/IGF-1 axes simultaneously.

HCG + BPC-157 For post-injury or post-surgical recovery, HCG's hormonal support and anti-inflammatory effects complement BPC-157's tissue repair and healing properties.

HCG + Tesamorelin For body composition research, Tesamorelin's GH-releasing and visceral fat-reducing effects complement HCG's potential lipolysis and testosterone support — targeting both metabolic and hormonal pathways simultaneously.

HCG + SERM (Tamoxifen / Clomiphene) The standard PCT protocol — HCG stimulates testicular testosterone production while the SERM prevents estrogen-related side effects and supports HPTA recovery by blocking estrogen feedback at the pituitary.

HCG + Kisspeptin Kisspeptin stimulates the HPG axis upstream of LH/FSH, while HCG acts downstream at the testicular level. Together they address both the signalling and receiving ends of the reproductive hormone axis.

---

Disclaimer: The information presented on this page is provided for educational and research purposes only. HCG (Human Chorionic Gonadotropin) is a Schedule 4 prescription medication in Australia. It is not approved by the TGA for weight loss, anti-aging, or body composition purposes. This product is not intended to diagnose, treat, cure, or prevent any disease. All dosing information is derived from published research literature and clinical protocols, and is provided for educational reference only. Riptide Health does not warrant the accuracy of this information and assumes no liability for its application. Consult a qualified healthcare professional before using any hormone or peptide compound.